EyePedia™ - The Eye Encyclopedia

First Retinal Prosthesis Study Of Its Kind Seeks To Partially Restore Vision ...
19 Nov 2008 at 9:00am
Second Sight® Medical Products, Inc., the leading developer of retinal prostheses for the blind, announced that it will increase patient enrollment for the ArgusTM II Retinal Implant study throughout clinical trials sites within Europe. The three-year feasibility study is currently underway in th...
Will Glaucoma Be The First Neurodegenerative Disease To Be Cured?
19 Nov 2008 at 2:00am
"More than in any preceding year," says Glaucoma Research Foundation (GRF) President and CEO Thomas M. Brunner, "there is a heightened sense of anticipation around the annual Research Overview by the four principal investigators of the GRF-funded Catalyst For a Cure (CFC) research consortium that...
Delcath Systems Granted Orphan-Drug Designations For Cutaneous And Ocular Mel...
19 Nov 2008 at 12:00am
Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary liver cancer treatment for melanoma metastatic to the liver, announced that the United States Food and Drug Administration ("FDA") granted to Delcath two orphan-drug applications for the drug melphalan. De...
Experimental Drug RGN-259 Promotes Healing In Patients With Non-Healing Corn...
18 Nov 2008 at 10:00am
REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that its ophthalmic drug candidate, RGN-259, was used to treat four neurotrophic keratitis patients with non-healing eye ulcers caused primarily by the herpes zoster virus under a "Compassionate Use" IND (Investigational New Drug applic...
Novagali Pharma S.A. Withdraws Its Marketing Authorisation Applicationfor Vek...
18 Nov 2008 at 8:00am
The European Medicines Agency (EMEA) has been formally notified by Novagali Pharma S.A. of its decision to withdraw its application for a centralised marketing authorisation for the medicine Vekacia (ciclosporin) 0.05% eye drops. Vekacia was expected to be used for the treatment of vernal...
New Research Into Drug Delivery To Treat Eye Disease Highlighted By Conferenc...
18 Nov 2008 at 8:00am
Researchers are investigating microneedles, nanoparticles and polymer carriers as potential new techniques to combat the leading cause of visual impairment and blindness in the United States, according to a report from the Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. The...
Promising Proof-of-Concept Data For Lpath's Ocular Drug Candidate ISONEP(TM) ...
17 Nov 2008 at 4:00am
Lpath, Inc. (OTCBB: LPTN) today announced that the laboratory of Peter Campochiaro, MD at Johns Hopkins University School of Medicine(1) recently published peer-reviewed findings of a research study of iSONEP(TM), Lpath's Phase 1 anti-S1P antibody, demonstrating promising results ...
Patents Issued For Inotek Pharmaceuticals' Lead Clinical Compounds In Glaucom...
16 Nov 2008 at 12:00am
Inotek Pharmaceuticals Corporation announced today that the United States Patent and Trademark Office has issued two new patents covering the Company's two lead clinical compounds. US Patent number 7,423,144 relates to INO-8875, in clinical development as a novel treatment for glaucoma and US Pat...

Our Mission:
Provide consumers with faster, easier access to the information, products and services they want.

We search the major search engines and remove the duplicates, the advertising sites, the pop-up ads, and anything that might harm your computer. Then we include all the related products and services in this easy-to-remember place where you spend less time searching, and more time finding what you want about eyes.